The article "Possibility of using a polyvalent bacteriophage in the technology of delayed administration of antibiotics in patients with acute rhinosinusitis" by Al Hariri M.Zh., Popovich V.I., Koshel I.V. (Ivano-Frankivsk National Medical University) will be published in issue No. 4, 2020, of the international journal "Otolaryngology. Eastern Europe"

Resume

Acute rhinosinusitis can be classified as acute bacterial rhinosinusitis in only 0.5-5% of cases, so no more than 5% of patients with acute rhinosinusitis require antibiotic therapy. However, unjustified antibiotic therapy is prescribed in 54-77% of cases of acute rhinosinusitis.

The aim of the study was to determine the effectiveness of a polyvalent bacteriophage in the technology of delayed administration of antibiotics in patients with acute post-viral rhinosinusitis.

Methods : The study included 155 adult patients with acute postviral rhinosinusitis who received a polyvalent bacteriophage in addition to standard therapy or standard therapy alone.

Evaluation criteria : reduction in the severity of disease symptoms, assessed on a point scale according to the MSS scale, at each visit compared to the first visit, frequency of antibiotic prescriptions.

Results . The use of a polyvalent bacteriophage in addition to standard therapy for acute postviral rhinosinusitis provides a clinically significant and reliable reduction in the severity of rhinorrhea, nasal congestion, and postnasal drip on the third day of observation (p<0.05). Similar symptoms were observed in the control group on the fifth day. Thus, in the first days of treatment, patients in the study group demonstrated a "therapeutic advantage" compared to the control group, allowing for a positive assessment of the disease dynamics and avoiding unnecessary antibiotic prescriptions. The use of a polyvalent bacteriophage in a deferred antibiotic prescription strategy for patients with acute postviral rhinosinusitis reduces the prescription of antibacterial drugs by 20%. No adverse effects were reported in any patient during treatment.

Conclusion . The use of a polyvalent bacteriophage in addition to standard therapy for the treatment of acute postviral rhinosinusitis has been shown to provide a significant clinical effect in the first days of treatment. Nasal discharge (rhinorrhea and postnasal drip) and nasal congestion are significantly reduced compared to the control group. This clinical effect in the first days of treatment reduces the need for antibacterial medications by 20%. Inclusion of this drug in the treatment regimen may be recommended for patients with acute postviral rhinosinusitis as part of a strategy for delayed antibiotic use.